MX2022014856A - Derivado de anticuerpo anti-nr1 humano. - Google Patents
Derivado de anticuerpo anti-nr1 humano.Info
- Publication number
- MX2022014856A MX2022014856A MX2022014856A MX2022014856A MX2022014856A MX 2022014856 A MX2022014856 A MX 2022014856A MX 2022014856 A MX2022014856 A MX 2022014856A MX 2022014856 A MX2022014856 A MX 2022014856A MX 2022014856 A MX2022014856 A MX 2022014856A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- human
- nmdar
- present
- patients
- Prior art date
Links
- 208000008958 Anti-N-Methyl-D-Aspartate Receptor Encephalitis Diseases 0.000 abstract 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 3
- 230000001717 pathogenic effect Effects 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención aborda el problema de proporcionar un nuevo agente terapéutico para el tratamiento de pacientes con encefalitis anti-NMDAR. Los pacientes con encefalitis anti-NMDAR tienen un anticuerpo anti-NR1 humano patogénico que induce la internalización de NMDAR en la superficie celular. Como resultado, la función de NMDAR se debilita en el cerebro de los pacientes. Los presentes inventores descubrieron que el anticuerpo anti-NR1 humano de un solo brazo de acuerdo con la presente invención se une a NR1 de manera competitiva con el anticuerpo patogénico anti-NR1 humana e inhibe la internalización de NMDAR por el anticuerpo anti-NR1 humano patogénico para exhibir así un efecto terapéutico en encefalitis anti-NMDAR. Por consiguiente, la presente invención proporciona un anticuerpo anti-NR1 humano de un solo brazo, un polinucleótido que codifica el anticuerpo, un vector de expresión que contiene el polinucleótido, una célula huésped transformada por el vector de expresión, un método para producir el anticuerpo, una composición farmacéutica que comprende el anticuerpo, un uso del anticuerpo en la fabricación de la composición farmacéutica y un método para tratar la encefalitis anti-NMDAR usando el anticuerpo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020092105 | 2020-05-27 | ||
PCT/JP2021/019929 WO2021241616A1 (ja) | 2020-05-27 | 2021-05-26 | 抗ヒトnr1抗体誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022014856A true MX2022014856A (es) | 2023-03-06 |
Family
ID=78744563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022014856A MX2022014856A (es) | 2020-05-27 | 2021-05-26 | Derivado de anticuerpo anti-nr1 humano. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230220070A1 (es) |
EP (1) | EP4159859A1 (es) |
JP (1) | JPWO2021241616A1 (es) |
KR (1) | KR20230029671A (es) |
CN (1) | CN116133684A (es) |
AU (1) | AU2021281828A1 (es) |
BR (1) | BR112022023931A2 (es) |
CA (1) | CA3180470A1 (es) |
IL (1) | IL298537A (es) |
MX (1) | MX2022014856A (es) |
WO (1) | WO2021241616A1 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
EP2805972A1 (en) | 2013-05-21 | 2014-11-26 | PAION Deutschland GmbH | Novel antibody useful in neurological or neurodegenerative disorders |
JP2018535922A (ja) * | 2015-08-17 | 2018-12-06 | ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー.ファウ.(デーツェットエンエー) | 抗N−メチル−D−アスパラギン酸(NMDA)受容体抗体の結合領域に結合する抗体または抗体フラグメントまたは非Ig足場 |
-
2021
- 2021-05-26 AU AU2021281828A patent/AU2021281828A1/en active Pending
- 2021-05-26 JP JP2022526603A patent/JPWO2021241616A1/ja active Pending
- 2021-05-26 EP EP21812316.4A patent/EP4159859A1/en active Pending
- 2021-05-26 KR KR1020227045463A patent/KR20230029671A/ko unknown
- 2021-05-26 BR BR112022023931A patent/BR112022023931A2/pt unknown
- 2021-05-26 MX MX2022014856A patent/MX2022014856A/es unknown
- 2021-05-26 WO PCT/JP2021/019929 patent/WO2021241616A1/ja unknown
- 2021-05-26 CA CA3180470A patent/CA3180470A1/en active Pending
- 2021-05-26 IL IL298537A patent/IL298537A/en unknown
- 2021-05-26 CN CN202180058596.9A patent/CN116133684A/zh active Pending
-
2022
- 2022-11-17 US US18/056,635 patent/US20230220070A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112022023931A2 (pt) | 2023-04-11 |
WO2021241616A1 (ja) | 2021-12-02 |
IL298537A (en) | 2023-01-01 |
AU2021281828A1 (en) | 2023-02-02 |
US20230220070A1 (en) | 2023-07-13 |
KR20230029671A (ko) | 2023-03-03 |
CA3180470A1 (en) | 2021-12-02 |
CN116133684A (zh) | 2023-05-16 |
JPWO2021241616A1 (es) | 2021-12-02 |
EP4159859A1 (en) | 2023-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Beasley Jr et al. | Efficacy of olanzapine: an overview of pivotal clinical trials | |
MX2022006365A (es) | Receptores de antigeno quimerico cd19 y cd22 y usos de los mismos. | |
DE14163637T1 (de) | Transdermales therapeutisches System, Rivastigmin enthaltend | |
EA201800499A1 (ru) | Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор | |
MY197632A (en) | Method and composition for preventing, treating or relieving bone diseases | |
MX2022014856A (es) | Derivado de anticuerpo anti-nr1 humano. | |
MX2023005408A (es) | Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina. | |
MX2023002001A (es) | Anticuerpos anti-par-2 y metodos de uso de los mismos. | |
Oki et al. | Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma | |
CR20210507A (es) | Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso | |
Sardone et al. | Effect of mechanical strain on the collagen VI pericellular matrix in anterior cruciate ligament fibroblasts | |
MX2023008923A (es) | Composicion farmaceutica que comprende un derivado de difenilpirazina. | |
TWI670069B (zh) | 用於維持塡充劑作用之組合物 | |
Amiri et al. | Comparison of granisetron and metoclopramide in the treatment of pain and emesis in migraine patients: A randomized controlled trial study | |
Lapierre | A review of trimipramine 30 years of clinical use | |
Malta | Biphasic relaxant curves to glyceryl trinitrate in rat aortic rings: evidence for two mechanisms of action | |
AR029680A1 (es) | Metodos para el tratamiento o profilaxis de efectos patogenos mediados por aldosterona en un sujeto | |
Ueda et al. | Higher plasma 5-hydroxyindoleacetic acid levels are associated with SSRI-induced nausea | |
KARAKI et al. | CHANGES IN TENSION, Ca MOVEMENT AND METABOLISM OF GUINEA PIG TAENIA COLI IN VARYING CONCEN-TRATIONS OF EXTERNAL Na AND K | |
ZA202200331B (en) | Naltrexone formulation | |
BR0314651A (pt) | Composição farmacêutica, e, método para tratar infecção pelo hvi | |
MX2021013222A (es) | Metodos para tratar el cancer con un anticuerpo anti-pd-l1. | |
Ivanets et al. | Venlafaxine in the treatment of moderate and severe depression: approaches to increasing treatment efficacy | |
Foreman et al. | Alterations in K+-evoked release of 3H-norepinephrine and contractile responses in urethral and bladder tissues induced by norepinephrine reuptake inhibition | |
MX2023001678A (es) | Metodos para tratar esclerosis multiple con ocrelizumab. |